New era in metastatic melanoma

References 

1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116
   • MEDLINE
2. Bedikian A, Milward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dicarbazine in patients with advanced melanoma. J Clin Oncol. 2006;24:4738–4745
   • CrossRef
3. Curtin JA, Fridly J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. NEJM. 2005;353:2135–2147
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
   • MEDLINE
   • CrossRef
5. Garbe, C., Peris, K., Hauschild, A. et al. 2009. Diagnosis and treatment of melanoma. European Consensus Based Interdisciplinary Guideline. European Journal of Cancer. Available online, 01.12.09.
6. Hodi FS, Friedlander P, Corless CL, et al. Major Response to imatinib mesylate in kit-mutated melanoma. J Clin Oncol. 2008;26:2046–2051
7. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96
   • CrossRef
8. Maio M, Lebbe C, Chiarion Sileni C, et al. Long-Term Survival in Advanced Melanoma Patients Treated With Ipilimumab at 10 mg/kg: Ongoing Analyses from completed Phase II Trials. P9307. ECCO/ESMO; 2009;
9. O'Day SJ, Kim KB, Sosman JA, et al. BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination with Carboplatin plus Paclitaxel in Patients with Previously Untreated Advanced Melanoma. Abstract 23LBA ECCO/ESMO; 2009;
10. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
    • MEDLINE
    • CrossRef
11. Pleasance E, Cheetham RK, Stephens PJ. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2009;463:Advanced online publication 16.12.09